Because re-expression of CD27 on MTB-specific CD4 T cells has been shown to occur very slowly upon TB treatment [10], these data are consistent with the hypothesis that TB−/HIV+ subjects with CD27− MTB-specific CD4 T cell responses, might have been exposed to subclinical, low levels of MTB replication before commencing ARV treatment. The gene discussed is CD27; the disease is tuberculosis.